title: Inhibition of human colon cancer cell growth by antisense oligodeoxynucleotides targeted at basic fibroblast growth factor.
abstract: BACKGROUND
  Basic fibroblast growth factor has been shown to be mitogenic in colon cancer cell lines. In human malignant melanoma cells, antisense oligodeoxynucleotides targeted against basic fibroblast growth factor messenger RNA significantly inhibit cell growth. However, the efficacy of such an antisense oligodeoxynucleotide strategy has not been evaluated for colon cancer cells.
  
  
  OBJECTIVE
  To investigate whether basic fibroblast growth factor can stimulate the growth of HT-29 human colon cancer cells and whether antisense oligodeoxynucleotides can inhibit growth of these cells at baseline.
  
  
  METHODS
  Western blotting analyses were used to confirm the presence of basic fibroblast growth factor protein in this cell line. Cell growth was assessed after 2, 4 and 6 days of treatment by cell counting using the trypan blue exclusion method. Phosphorothioate-modified oligodeoxynucleotides (10 microM) were used, complementary to codon 60 of the basic fibroblast growth factor messenger RNA. Cationic liposomes (DOTAP) were used to enhance the cellular uptake of the oligodeoxynucleotides.
  
  
  RESULTS
  Western blotting demonstrated the presence of basic fibroblast growth factor protein in this cell line. Basic fibroblast growth factor (1-40 ng/mL) dose-dependently stimulated cell growth and peak values were obtained at a dose of 20 ng/mL. By contrast, antisense oligodeoxynucleotide treatment significantly inhibited cell growth compared with the sense oligodeoxynucleotide-treated cells (P=0.007). This inhibition was reversed by the addition of basic fibroblast growth factor, 20 ng/mL.
  
  
  CONCLUSIONS
  Treatment targeted against basic fibroblast growth factor messenger RNA inhibits growth of HT-29 human colon cancer cells. This finding may provide a rationale for the therapeutic use of antisense oligodeoxynucleotides targeted at basic fibroblast growth factor for the treatment of colon cancer.
authors.affiliation: VA Medical Center, Long Beach, California, USA. peter.netzer@insel.ch
authors.forename: P
authors.initials: P
authors.lastname: Netzer
authors.forename: M
authors.initials: M
authors.lastname: Domek
authors.forename: R
authors.initials: R
authors.lastname: Pai
authors.forename: F
authors.initials: F
authors.lastname: Halter
authors.forename: A
authors.initials: A
authors.lastname: Tarnawski
mesh_terms: D000818:Animals; D002412:Cations; D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival; D003110:Colonic Neoplasms / Q000188:drug therapy*; D005346:Fibroblast Growth Factors / Q000235:genetics*; D019073:HT29 Cells; D006801:Humans; D008081:Liposomes / Q000378:metabolism; D016376:Oligonucleotides, Antisense / Q000235:genetics / Q000627:therapeutic use*; D010865:Pilot Projects; D012333:RNA, Messenger / Q000235:genetics
chemical_list: D002412:Cations; D008081:Liposomes; D016376:Oligonucleotides, Antisense; D012333:RNA, Messenger; D005346:Fibroblast Growth Factors